Bedoradrine
- Generic Name
- Bedoradrine
- Drug Type
- Small Molecule
- Chemical Formula
- C24H32N2O5
- CAS Number
- 194785-19-8
- Unique Ingredient Identifier
- 4EAR229231
- Indication
Investigated for use/treatment in asthma and labor and delivery.
MediciNova's Ibudilast Shows Promise in ALS Trial: Interim Analysis Reveals Strong Correlations
• MediciNova's COMBAT-ALS Phase 2/3 trial of MN-166 (ibudilast) in ALS shows positive correlations between 6-month and 12-month data for key metrics.
• The Data Safety Monitoring Board (DSMB) recommended the trial continue as planned, supporting the robustness of the study design.
• Patient assignments are expected to be completed by June 2025, with trial results anticipated in 2026, offering hope for ALS treatment advancements.
• MediciNova is supporting continued treatment through the FDA's Expanded Access Program, ensuring access to MN-166 for more ALS patients.
MediciNova's Ibudilast (MN-166) Shows Promise in ALS Treatment: Phase 2/3 Trial Update
• MediciNova presented an update on its Phase 2/3 COMBAT-ALS trial of MN-166 (ibudilast) for amyotrophic lateral sclerosis (ALS) at the 2024 Annual NEALS Meeting.
• The presentation highlighted the study design, scientific rationale, objectives, inclusion criteria, and enrollment status of the ongoing trial as of October 18, 2024.
• An NIH-funded Expanded Access Protocol (EAP) is underway to provide MN-166 (ibudilast) to ALS patients ineligible for the COMBAT-ALS trial, supported by a $22 million grant.
• MN-166 (ibudilast) is a small molecule compound targeting PDE4 and inflammatory cytokines, with potential benefits for neurodegenerative diseases like ALS.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath